OpenFold
- Company typePrivate
- Founded2021
- HeadquartersDavis, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
OpenFold firmographics
Firmographics- Name
- OpenFold
- Legal name
- OpenFold Consortium
- Website
- https://openfold.io
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
OpenFold industry classification
Industry- Product category
- Bioinformatics and AI-driven Protein Structure Prediction Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where OpenFold is headquartered
LocationHeadquarters
- HQ city
- Davis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OpenFold business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations
Revenue model
- Consortium Membership Contributions: OpenFold is a non-profit consortium. Organizations join as members contributing financially, through FTE (full-time equivalent) support, or in-kind resources (computing, data). These contributions sustain the consortium's operations and roadmap development. The project is hosted by the Open Molecular Software Foundation (OMSF), a 501(c)(3) non-profit.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels5 records
OpenFold product offering
Product offeringCore offering
OpenFold develops and maintains open-source AI foundation models for predicting 3D biomolecular structures, including OpenFold (protein folding), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction), and OpenFold3 (co-folding of proteins with nucleic acids and small molecules). All models, training pipelines, datasets, and pre-trained weights are released under the permissive Apache 2.0 license for both research and commercial use.
Product overview
OpenFold is a non-profit AI research consortium developing open-source software tools for biology and drug discovery, hosted by the Open Molecular Software Foundation (OMSF). The core offering is OpenFold3, an open-source foundation model for predicting 3D structures of proteins, nucleic acids, and their complexes. The product portfolio includes OpenFold (core protein structure prediction), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction without MSA), OpenFold-SmallMolecule (under development for ligand interactions), and OpenStability (protein stability prediction). Third-party tools built on OpenFold include AQAffinity (binding affinity prediction) and ApherisFold (privacy-preserving deployment). All models, training data, and code are released under permissive Apache 2.0 license, with inference code, training pipelines, and pre-trained weights available via GitHub and AWS Registry of Open Data.
Differentiator
Problem solved
Functional benefit
Brands
- OpenFold: Core platform for high-accuracy protein folding predictions
- OpenFold-Multimer
- OpenFold-SoloSeq
- OpenFold3
- OpenFold-SmallMolecule
- OpenStability
Products and services
- OpenFold
- OpenFold-Multimer
- OpenFold-SoloSeq
- OpenFold3
- OpenStability
Quantifiable outcome
- 85% cost savings in computational infrastructure using AWS EC2 Capacity Blocks for ML and Spot Instances
- +2 more outcomes
Companies that use OpenFold
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
OpenFold technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
OpenFold partnerships and signals
Strategic signalPartnerships
33 partnerships are on record, tiered core and minor.
- Nxera PharmacoreNxera Pharma joined OpenFold consortium to leverage state-of-the-art open-source structural prediction models and create synergies with its proprietary NxWave platform for GPCR target-focused drug discovery.
- SandboxAQcoreContinued collaboration on OpenFold3 release preview and AQAffinity model for rapid protein-ligand binding affinity prediction.
- ApheriscoreApheris joined contributing privacy-preserving infrastructure enabling secure AI training and benchmarking on proprietary data without compromising confidentiality. Offers ApherisFold integration.
- Johnson & JohnsoncoreJohnson & Johnson joined bringing deep expertise in AI and biomedical research to advance the consortium's goal of accelerating drug discovery.
- Structure TherapeuticsminorSmall-molecule therapeutics company joined as biotech member contributing to drug discovery applications.
- COGNANOminorAntibody discovery company joined contributing expertise in AI-powered antibody development for therapeutic applications.
- TamarindminorBiotech company joined as consortium member supporting open AI infrastructure for biology.
- Unnatural ProductsminorSmall-molecule therapeutics company joined contributing to drug discovery pipeline applications.
- VisterraminorBiotech company joined contributing expertise in AI-powered therapeutic development.
- University of Washington (Institute for Protein Design)coreLed by Nobel Laureate David Baker. OpenFold launched research fellowship supporting graduate students and postdocs working on next-generation models for antibody-antigen design and structure prediction.
- SandboxAQcoreSandboxAQ contributed to OpenFold3 development enhancing protein-molecule structure prediction. Built AQAffinity on top of OpenFold3 for structure-free drug potency prediction under Apache 2.0 license.
- RochecoreGlobal pharmaceutical company joined as pharma consortium member contributing to open AI infrastructure for drug discovery.
- Bristol Myers SquibbcoreBristol Myers Squibb joined as consortium member representing global pharma involvement in open AI infrastructure for biology and drug discovery.
- Novo NordiskcoreNovo Nordisk partnered on OpenFold3 development, collaborating with Columbia University and AWS to build cutting-edge open-source AI model for protein structure prediction. Achieved 85% cost savings using AWS EC2 Capacity Blocks.
- AstexminorSmall molecule therapeutics company joined bringing expertise in fragment-based drug discovery and AI-driven design.
- BiogenminorBiopharmaceutical company joined contributing expertise in neuroscience and novel biologic therapies.
- CongruenceminorComputational chemistry company joined contributing to AI-driven drug design methodologies.
- Polaris QuantumminorQuantum computing company joined bringing expertise in quantum computing applications for drug discovery.
- PsivantminorComputational molecular design company joined; Woody Sherman, Chief Innovation Officer, serves as OpenFold Chairperson and Executive Committee Chair.
- Northwestern University (Rocklin Lab)coreProf. Gabriel Rocklin leads protein studies funded by OpenFold. Lab released mega-scale protein stability dataset advancing biomolecular AI research.
- BayercoreBayer joined as pharmaceutical member represented on Technical Advisory Council. Contributing to drug discovery applications of open AI infrastructure.
- Dassault Systèmes (BIOVIA)coreDassault Systèmes joined in November 2022 to integrate AlphaFold AI models into its 3DEXPERIENCE platform for pharmaceutical research through BIOVIA brand.
- CHARM TherapeuticsminorDeep learning company joined contributing to AI-driven drug discovery and protein structure prediction.
- BaseCamp ResearchminorAI company joined contributing to biological data and protein analysis capabilities.
- NVIDIAcoreNVIDIA joined as consortium member providing GPU computing support and expertise. OpenFold3 is deployable via NVIDIA NIM inference for optimized performance.
- UCBcoreUCB joined as pharma consortium member contributing expertise in computational molecular design and CADD.
- Valence Labs (Recursion)minorAI-powered drug discovery company (powered by Recursion) joined contributing computational biology expertise.
- Columbia University (AlQuraishi Lab)coreCo-founding academic institution; Prof. Mohammed AlQuraishi leads development. Gustaf Ahdritz, PhD student in the lab, is lead developer of OpenFold.
- ArzedacoreFounding member and Executive Committee representation (CEO Alexandre Zanghellini). Protein design company using AI for enzyme and biosensor development.
- Cyrus BiotechnologycoreFounding member and Executive Committee representation (CEO Lucas Nivon). Provides protein modeling tools for biotech and pharma markets.
- Outpace BiocoreFounding member and Vice Chairperson representation (Brian Weitzner). Cancer immunotherapy company focused on protein engineering.
- Amazon Web Services (AWS)coreAWS provides cloud computing infrastructure, EC2 Capacity Blocks for ML, and hosts training data on AWS Registry of Open Data through Open Data Sponsorship Program. Achieved 85% cost savings for OpenFold3 training using Spot Instances.
- MicrosoftcoreSupporting member providing DeepSpeed technology and research collaboration for distributed training optimization.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
OpenFold competitors and assessment
Company assessmentBroad incumbents
- Google DeepMind (AlphaFold): Creator of AlphaFold and AlphaFold3, the proprietary benchmark OpenFold3 is designed to match. Operates with vastly larger compute resources and feeds into Alphabet's Isomorphic Labs drug discovery pipeline.
- Isomorphic Labs: Alphabet-owned commercial drug discovery company built on AlphaFold. Competes for the same pharma partnerships OpenFold targets and represents the commercial endpoint of the closed-source alternative.
- Schrödinger: Computational chemistry and drug discovery platform combining physics-based simulation with AI/ML. Sells to the same large pharma and biotech customers OpenFold consortium members represent.
- Recursion: AI-driven drug discovery company using high-throughput biology and machine learning; operates Valence Labs as its AI research arm (an OpenFold consortium member). Competes for the same pharma AI partnerships.
- Insilico Medicine: AI-driven drug discovery company operating its own foundation models for biology and chemistry. Competes in the same AI-for-drug-discovery category and serves overlapping pharma customers.
Emerging players
- EvolutionaryScale: AI protein design company building frontier foundation models for biology (ESM3). Comparable to OpenFold in modality (protein language/structure models) but pursuing a venture-backed, partially closed commercialization path.
- Profluent Bio: AI protein design company using large language models to design novel proteins. Competes with OpenFold in the protein design space and serves similar biotech and pharma customers with proprietary offerings.
- Cradle Bio: AI-driven protein engineering company focused on designing improved proteins for therapeutics and industrial applications. Comparable technology stack and customer base to OpenFold's biotech/biopharma users.
- Chai Discovery: AI foundation models for molecular structure prediction and design, with explicit focus on protein-ligand co-folding. Direct competitor to OpenFold3 in biomolecular co-folding capabilities.
- Genesis Therapeutics: AI-driven drug discovery company with proprietary molecular AI models for structure prediction and protein-ligand binding. Comparable in capability and target customers to OpenFold's drug discovery focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OpenFold social profiles
Digital presenceOpenFold financial estimates
Financial estimateRevenue estimate
Valuation estimate
OpenFold leadership team
Management profileNumber of profiles
Profiles14 records
OpenFold funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OpenFold M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OpenFold
What does OpenFold do?
OpenFold develops and maintains open-source AI foundation models for predicting 3D biomolecular structures, including OpenFold (protein folding), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction), and OpenFold3 (co-folding of proteins with nucleic acids and small molecules). All models, training pipelines, datasets, and pre-trained weights are released under the permissive Apache 2.0 license for both research and commercial use.
Is OpenFold a public or private company?
OpenFold is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was OpenFold founded?
OpenFold was founded in 2021. It employs 1 to 10 people.
Where is OpenFold based?
OpenFold is headquartered in Davis, United States, in the North America region.
How does OpenFold make money?
One revenue line is on record: consortium Membership Contributions.
Who are OpenFold's main competitors?
Broad incumbents on record are Google DeepMind (AlphaFold), Isomorphic Labs, Schrödinger, Recursion and Insilico Medicine. Emerging players are EvolutionaryScale, Profluent Bio, Cradle Bio, Chai Discovery and Genesis Therapeutics.
Does OpenFold have an API?
No public API is recorded for OpenFold.
What industry is OpenFold in?
OpenFold's product category is Bioinformatics and AI-driven Protein Structure Prediction Software. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 7372.